Most patients with advanced or metastatic cancer do not undergo genomic testing, according to a study published April 7 in JAMA Network Open.
Researchers from Salt Lake City-based Huntsman Cancer Institute, Dallas-based University of Texas Southwestern Medical Center, Kansas City-based University of Kansas Cancer Center and Cleveland-based University Hospitals Seidman Cancer Center, analyzed patient data from 280 U.S. cancer clinics to assess uptake of next-generation sequencing.
Here are three things to know from the study:
- Between Jan. 1, 2018, and Dec. 30, 2022, 63,294 patients with advanced or metastatic cancer underwent next-generation sequencing.
Next-generation sequencing uptake increased among patients diagnosed in 2022 compared with 2018 across all cancer types. - “Although the 1-year cumulative incidence of next-generation sequencing improved over time across all cancer types, the majority of patients with cancer did not undergo next-generation sequencing,” the study authors wrote.
- Patients with low socioeconomic status, Black or Hispanic patients, and patients with Medicaid or Medicare coverage had a significantly longer time between diagnosis and next-generation sequencing.
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
